Cutia Therapeutics says China regulator accepts CU-20101 botulinum toxin BLA for review

• Cutia Therapeutics’ China regulator accepted its BLA for CU-20101, an injectable botulinum toxin type A product.
• The filing targets an aesthetic indication to improve moderate-to-severe glabellar lines.
• The company highlighted a manufacturing process without animal-derived materials or human albumin, citing potential safety advantages.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260903-12317181), on September 02, 2026, and is solely responsible for the information contained therein.